Top Page
Fusen Pharmaceutical Co., Ltd.
(1652)
Fusen Pharmaceutical Co., Ltd. (1652) vs. iShares MSCI Hong Kong ETF (EWH)
Fusen Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Fusen Pharmaceutical Co., Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 326.03M | 565.61M | 491.76M | 385.66M | 486.85M |
| Gross Profit | 162.64M | 299.51M | 225.02M | 211.13M | 266.07M |
| EBITDA | -39.07M | 18.93M | 49.90M | 55.82M | 110.30M |
| Net Income | -188.78M | -36.28M | -34.65M | 16.64M | 70.13M |
Balance Sheet | |||||
| Total Assets | 1.24B | 1.34B | 1.35B | 1.24B | 1.24B |
| Cash, Cash Equivalents and Short-Term Investments | 21.06M | 34.85M | 128.11M | 81.70M | 312.53M |
| Total Debt | 383.69M | 344.12M | 228.38M | 240.69M | 198.50M |
| Total Liabilities | 869.80M | 781.52M | 737.38M | 582.39M | 583.10M |
| Stockholders Equity | 369.67M | 563.52M | 614.17M | 658.17M | 659.44M |
Cash Flow | |||||
| Free Cash Flow | 57.43M | -161.84M | 86.63M | -62.37M | 94.56M |
| Operating Cash Flow | 133.73M | -73.33M | 110.49M | 47.77M | 153.21M |
| Investing Cash Flow | -163.42M | -108.32M | -13.13M | -282.98M | -68.20M |
| Financing Cash Flow | 15.99M | 88.50M | -51.77M | 20.53M | -116.33M |
Fusen Pharmaceutical Co., Ltd. Technical Analysis
Fusen Pharmaceutical Co., Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$745.36M | 33.46 | 1.87% | 9.43% | -1.99% | -81.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$595.53M | -3.16 | -40.38% | ― | -43.46% | -96.48% | |
48 Neutral | HK$573.11M | -3.37 | ― | ― | ― | ― | |
48 Neutral | HK$211.34M | -40.20 | -8.71% | ― | 2.54% | 33.33% | |
44 Neutral | HK$268.76M | -3.99 | -13.08% | ― | -19.28% | -42.27% | |
41 Neutral | HK$187.23M | -3.59 | -33.22% | ― | -17.32% | 55.74% |
Fusen Pharmaceutical Co., Ltd. Corporate Events
Fusen Pharmaceutical said its wholly owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology has received Chinese regulatory approval to market Compound Potassium Hydrogen Phosphate Injection, a Class B reimbursable drug used as a parenteral phosphate supplement and for treating hypophosphatemia in adult and pediatric patients when oral or enteral therapy is unsuitable. The new-generation phosphorus–potassium formulation, designed to rapidly correct phosphorus deficiency while stabilizing membrane potential and reducing risks such as rhabdomyolysis and arrhythmia, targets a domestic market that generated RMB343 million in 2023 and RMB413 million in 2024, and its launch broadens Fusen’s nutritional supplement portfolio and strengthens its positioning in hospital nutrition and electrolyte management, potentially enhancing its presence in China’s parenteral nutrition segment.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Company Limited has announced a change of auditor, with KPMG resigning effective 24 December 2025 after the two sides failed to agree on the audit fee for the Group’s 2025 consolidated financial statements. The board and audit committee stated there were no other disagreements or matters requiring shareholder attention and expect no material impact on the annual audit or the release of 2025 results. Following a review of audit proposals, experience, resources, independence and market reputation in line with guidelines from Hong Kong’s Accounting and Financial Reporting Council, the audit committee recommended and the board approved the appointment of CCTH CPA Limited as the new auditor until the next annual general meeting. Management said the change is intended to support cost control and reduce overall operating expenses, positioning the Group to better manage future business development while maintaining audit quality, which they view as being in the interests of the company and its shareholders.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration of the PRC for the consistency evaluation of its Nicardipine Hydrochloride Injection. This product, used for emergency management of perioperative hypertension, has seen significant sales growth in China, reflecting its efficacy and market acceptance. The approval enhances Fusen’s product offerings, positioning it strongly within the market for hypertensive emergency treatments.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. announced that its subsidiary, Jiaheng Pharmaceutical Technology, has received approval from the National Medical Products Administration of the PRC to market ‘Measartan Potassium Tablets’ for treating primary hypertension. This product, containing azilsartan medoxomil potassium, enhances the company’s portfolio in the blood circulatory system field, offering a new treatment option for hypertension with significant and stable effects, and aligns with the company’s strategy to strengthen its market position in the antihypertensive drug sector.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. announced the approval of its ‘Enzalutamide Soft Capsule’ for marketing in China, targeting non-metastatic and metastatic castration-resistant prostate cancer. This product, developed by its subsidiary Jiaheng Pharmaceutical Technology, aligns with international standards and offers a favorable risk-benefit ratio for patients, enhancing the company’s therapeutic offerings and potentially strengthening its market position in prostate cancer treatment.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. announced that its Metformin Empagliflozin Tablets were selected in the eleventh batch of China’s National Centralised Medicines Procurement. This selection is a significant development for the company, potentially enhancing its market position and offering growth opportunities in the Chinese pharmaceutical market.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. announced a supplemental disclosure regarding the disposal of its entire equity interests in Henan Fusen Intelligent Energy Conservation Technology Co., Ltd. The consideration for this transaction was determined through negotiations based on the appraised net asset value of approximately RMB73.4 million. The valuation, conducted by an independent valuer, utilized the asset approach due to the target company’s short operational history, making other valuation methods less reliable.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Company Limited has announced the composition of its board of directors and their respective roles, highlighting the leadership structure within the company. The announcement details the membership of three board committees, which are crucial for the company’s governance and operational oversight, potentially impacting its strategic direction and stakeholder engagement.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.
Fusen Pharmaceutical Co., Ltd. has announced significant changes in its board composition effective from September 30, 2025. Mr. Sze Wing Chun has resigned as an independent non-executive director and chairman of the Audit Committee, while Mr. Yu Ho Ming has been appointed as an independent non-executive director and a member of the Audit Committee. Additionally, Mr. Lee Kwok Tung Louis has been appointed as the chairman of the Audit Committee. These changes are expected to bring new expertise and perspectives to the company’s governance, potentially impacting its strategic direction and stakeholder relations.
The most recent analyst rating on (HK:1652) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Fusen Pharmaceutical Co., Ltd. stock, see the HK:1652 Stock Forecast page.